Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy
- 3 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 133 (1), 89-97
- https://doi.org/10.1007/s10549-011-1693-x
Abstract
Several adverse effects of chemotherapy treatments have been described, and most of these effects are associated with direct interactions between blood cells and indirect effects generated during the oxidative metabolism of antineoplastic drugs. In this study we evaluated the oxidative systemic status and hematological profiles of breast cancer patients with advanced ductal infiltrative carcinoma treated with doxorubicin (DOX) or paclitaxel (PTX) within 1 h after chemotherapy. Blood analyses included evaluation of hemogram, pro-oxidative markers, and antioxidant status. The results showed that advanced breast cancer diseased (AD) patients without previous chemotherapy presented anemia and high oxidative stress status characterized by elevated levels of lipid peroxidation and nitric oxide, and reduced catalase activity when compared with controls. DOX-treated patients exhibited increased anemia and reduced antioxidant status, which was revealed by decreases in reduced glutathione levels and the total antioxidant capacity of plasma; however, these changes did not lead to further increases in lipid peroxidation or carbonyl proteins when compared with the AD group. PTX-treated patients also showed increased anemia, lactate dehydrogenase leakage, and enhanced lipid peroxidation. These data reveal for the first time that patients subjected to chemotherapy with DOX or PTX present immediate systemic oxidative stress and red blood cell oxidative injury with anemia development. These findings provide a new perspective on the systemic redox state of AD and patients subjected to chemotherapy regarding oxidative stress enhancement and its possible involvement in the aggravation of chronic anemia.Keywords
This publication has 41 references indexed in Scilit:
- Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivoEuropean Journal Of Cancer, 2010
- Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stressFree Radical Biology & Medicine, 2010
- Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administrationBiomarkers, 2009
- An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast CancerPLOS ONE, 2008
- Genistein abrogates pre-hemolytic and oxidative stress damage induced by 2,2′-Azobis (Amidinopropane)Life Sciences, 2006
- Stimulation of Erythrocyte Phosphatidylserine Exposure by PaclitaxelCellular Physiology and Biochemistry, 2006
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administrationJournal of Biochemical and Molecular Toxicology, 2004
- Role of Red Blood Cells in Pharmacokinetics of Chemotherapeutic AgentsClinical Pharmacokinetics, 2003
- Free Radicals in Organic Chemistry J. Am. Chem. Soc. 1996, 118, 4226Journal of the American Chemical Society, 1996